Dacomitinib is an EGFR inhibitor, mostly used for NSCLC patients with specific exon 19 deletions or L858R mutations in exon 21. It’s one of those kinase inhibitors. They work by stopping the signal pathway the mutated EGFR sends out.
It comes in tablet form with 3 dosages, which are 15 mg, 30 mg, and 45 mg. They usually recommend taking 45 mg each day for the best effect. The tablets have a coating to keep them together, sort of like a sugar shell.
A pack has 30 tablets, which is enough for a whole month if you take 45 mg daily.
